15 citations
,
January 2023 in “Journal of Translational Autoimmunity” Melatonin may help treat skin conditions.
41 citations
,
July 2016 in “Journal of Investigative Dermatology” Dysplastic nevi have unique gene expressions, making them distinct from common melanocytic nevi.
2 citations
,
January 2024 in “Advances in Dermatology and Allergology” S100A7 and IL-17 may contribute to inflammation in lichen planopilaris.
December 2025 in “Cureus” Higher IL-17A and IL-23 levels are linked to alopecia areata severity and could help in tracking and treating the disease.
7 citations
,
July 2019 in “The Journal of Dermatology” Terbinafine effectively treated kerion celsi despite disrupted immune responses.
19 citations
,
August 2018 in “JAMA dermatology” Mesenchymal stem cells in people with Hidradenitis Suppurativa are more inflammatory, possibly contributing to the disease.
12 citations
,
March 2016 in “BBA clinical” Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.
8 citations
,
July 2018 in “European Journal of Dermatology” A medication may help with hair growth in psoriasis, and a skin condition might be linked to a specific bacteria.
3 citations
,
July 2018 in “European Journal of Dermatology” An elderly man's hair grew back after treatment with secukinumab, possibly due to reduced scalp inflammation or the medication's direct effects.
1 citations
,
May 2025 in “Fayoum University Medical Journal/Fayoum University Medical Journal ” Certain gene variations are linked to alopecia areata.
May 2026 in “SKIN The Journal of Cutaneous Medicine” Bimekizumab can improve scarring alopecia in severe psoriasis.
April 2017 in “Journal of Investigative Dermatology” Cholecystokinin may help reduce skin inflammation in psoriasis.
July 2016 in “Journal of Investigative Dermatology” R-spondin2 may help treat hair loss, gene differences could explain baldness, a peptide's regulation is linked to psoriasis, B-defensin gene copies may affect a skin condition's risk and severity, and potential markers and targets for alopecia areata were identified.
November 2025 in “The Journal of Immunology” Different γδ T cell types have unique roles in causing alopecia areata.
1 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
December 2024 in “Kufa Medical journal” Higher levels of IL-17A and IL-2 are linked to alopecia areata.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ixekizumab may be an effective first treatment for a rare skin condition causing hair loss.
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.
September 2017 in “Griffith Research Online (Griffith University, Queensland, Australia)” Blocking IL-17 can reduce joint inflammation in Ross River Virus infections.
July 2023 in “Journal of the European Academy of Dermatology and Venereology” Anti-IL17A therapy reduced venous leg ulcer size by 64% without major side effects.
2 citations
,
February 2024 in “Medicine” A mutation in the IL2RA gene increases the risk of alopecia areata.
Early genetic testing and new therapies like secukinumab are crucial for managing Netherton syndrome effectively.
November 2024 in “Journal of Investigative Dermatology” The study investigated the effects of bimekizumab (BKZ) on psoriatic skin, focusing on the Psoriasis Area and Severity Index (PASI) sub-components: erythema, thickness, and scaling. In the BE RADIANT trial, patients receiving BKZ showed significant reductions in these sub-scores by Week 8, with ≥95% improvement by Week 12, maintained through Week 48. Molecular analysis revealed complete normalization of gene signatures associated with these sub-components by Week 8. The study found a correlation between changes in interleukin (IL)17A/IL17F expression and gene expression changes, highlighting BKZ's impact on keratinocytes. The results demonstrate that molecular resolution precedes clinical skin clearance, with all sub-components being reliable indicators of BKZ response.
April 2018 in “Journal of Investigative Dermatology” Acne patients' skin, both with and without lesions, shows a strong immune response and higher antimicrobial activity.
January 2022 in “The Egyptian Journal of Hospital Medicine” Higher IL-21 levels may help predict alopecia areata activity.
April 2018 in “Journal of Investigative Dermatology” IL-17C is important in inflammatory skin diseases and could be a target for treatment.
3 citations
,
August 2019 in “Journal of The American Academy of Dermatology” Clascoterone safely promotes hair growth similar to minoxidil.
34 citations
,
January 2022 in “Frontiers in Immunology” IL-25 helps heal diabetic wounds by improving blood vessel and skin cell functions.
19 citations
,
December 2015 in “Journal of Investigative Dermatology” The protein p53 directly reduces the production of Keratin 17, a skin and hair protein, in rats with radiation dermatitis.
62 citations
,
June 2015 in “The Journal of Dermatology” People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.